total joint arthroplasty
Conditions
Interventions
TKA-control:not giving TXA
TKA-IV:1g of tranexamic acid intravenouly administered 10-15 minutes before the tourniquet was applied/inflated for 20 minutes and one more dose of 1g given at 3 hours after the first dose.
TKA-IA:2g of tranexamic acid injected into joint cavity after suturing joint capsule and the drainage clamped for 2 hours then activated.
TKA-combined:1g of tranexamic acid intravenously administered 10-15 minutes before the tourniquet was applied/inflated for 20 minutes and 2g tranexamic acid injected into joint cavity after suturing j
THA-control:not giving TXA
THA-IV:1g of tranexamic acid intravenously administered 10-15 minutes before incision for 20 minutes and one more dose of 1g given at 3 hours after the first dose.
THA-IA:2g of tranexamic acid injected into joint cavity after suturing joint capsule . The drain was closed for 2 hours and then activated.
THA-combined:1g of tranexamic acid intravenously administered 10-15 minutes before incision for 20 minutes and 2g of tranexamic acid injected into joint cavity after suturing joint capsule .The drain
Sponsors
Drum Tower Hospital Affiliated to Medical School of Nanjing University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged 50-85 years old with degenerative osteoarthritis; 2) Patients using tranexamic acid in venous and local administration during unilateral primary total knee or hip arthroplasty; 3) Patients signing the informed consent .
Exclusion criteria
Exclusion criteria: 1) Patients with an allergy to tranexamic acid; 2) Patients with a history of coagulopathy; 3) Patients with a history of venous thrombembolism (deep venous thrombosis, superficial venous thrombosis, calf muscular venous thrombosis or pulmonary embolism); 4) Patients with severe liver (exceeds the normal upper limit by 2 times ) or kidney (creatinine clearance <15ml / min) dysfunction; 5) Patients with cardiovascular or cerebrovascular disease (with myocardial infarction ,cerebral infarction, angina pectoris, atrial fibrillation or shock history) 6) Patients with hemoglobin <100g / L or the use of anticoagulants (including warfarin, heparin, low molecular weight heparin, rivaroxaban, apixaban, dabigatran, hirudin Etc.) before surgery; 7) Patients with the use of antiplatelet agents (including aspirin, clopidogrel, prasugrel, ticagrelor, dipyridamole, ginkgo-damole) within 7 days before surgery; 8) Patients with the use of thrombolytic drugs (including urokinase, alteplase, etc.) within 7 days before surgery; 9) Patients with the use of Chinese patent drugs containing Salvia, Chuanxiong, hirudin for blood-activating and stasis-dissolving (including compound Danshen dripping pills, Xuefu Zhuyu oral liquid, Tongxinluo capsules, Lemai granules, Huoxuetongmai tablets, Danqi Tablets, Buchangnaoxintong Capsule, Shuxin Oral Liquid, Huoxing pill) within 7 days before surgery; 10) Patients with the use of hemostatic drugs (including tranexamic acid, aminocaproic acid, aminoacetic acid, phenol sulfonamide, pituitrin, norepinephrine, somatostatin, aprotinin, thrombin, coagulation factors, etc.) or plasma products for hemostasis within 7 days before surgery , or patients with massive hemorrhage within a month before surgery; 11) Patients with the perioperative use of drugs that can dilute or concentrate blood (eg mannitol, etc.) or elevate the level of blood cells..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraoperative blood loss;Postoperative discharge;Preoperative hemoglobin;Postoperative haemoglobin;Blood transfusion and transfusion rate;Tranexamic acid plasma concentration during period;Efficacy index of tranexamic acid;Postoperative thrombosis event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Preoperative HCT;Postoperative HCT;Hospital stay; | — |
Countries
China
Contacts
Public ContactQing Jiang
Drum Tower Hospital Affiliated to Medical School of Nanjing University
Outcome results
None listed